Background: Stroke risk is increased in AIDS patients, and highly active antiretroviral therapy (HAART) may accelerate atherosclerosis, but little is known about the incidence and risk factors for ischemic stroke in patients under HAART. We have studied the incidence, types of stroke and possible risk factors for cerebrovascular ischemic events in a large cohort of HIV-1-infected patients treated with HAART. Methods: We conducted a retrospective review of ischemic strokes and transient ischemic attacks occurring in a cohort of HIV-1-infected patients treated with HAART from 1996 to 2008. As a control group, consecutive unselected patients from the same cohort were included. Patients and controls were compared for demographic, clinical and laboratory variables, including vascular risk factors, data on HIV infection and duration of HAART. Variables with significant differences were included in a backward logistic regression model. Results: Twenty-seven cerebrovascular ischemic events occurred in 25 patients, with an incidence of 189 events (166 strokes) per 100,000 patients/year. Independent factors associated with cerebrovascular events were: history of high alcohol intake (OR 7.13, 95% CI 1.69–30.11; p = 0.007), a previous diagnosis of AIDS (OR 6.61, 95% CI 2.03–21.51; p = 0.002) and fewer months under HAART (OR 0.97, 95% CI 0.96–0.99; p < 0.001). Six patients (24%) had large artery atherosclerosis: they had a similar HAART duration to controls. Conclusions: Stroke incidence is high in patients with HIV-1 infection treated with HAART. Duration of HAART exerted a global protective effect for cerebrovascular ischemic events, and our results do not support a major role in large artery atherosclerosis stroke. High alcohol intake is a major risk factor for stroke in these patients.

Keywords:
Stroke, HIV, Antiretroviral therapy, Atherosclerosis
1.
Pinto AN: AIDS and cerebrovascular disease. Stroke 1996;27:538–543.
2.
Ortiz G, Koch S, Gomano JG, Forteza AM, Rabinstein AA: Mechanisms of stroke in HIV-1-infected patients. Neurology 2007;68:1257–1261.
3.
Tipping B, de Villiers L, Wainwright H, Candy S, Bryer A: Stroke in patients with human immunodeficiency virus infection. J Neurol Neurosurg Psychiatry 2007;78:1320–1324.
4.
Cole JW, Pinto AN, Hebel JR, Buchholz DW, Earley CJ, Johnson CJ, Macko RF, Price TR, Sloan MA, Stern BJ, Wityk RJ, Wozniak MA, Kittner SJ: Acquired inmunodeficiency syndrome and the risk of stroke. Stroke 2004;35:51–56.
5.
The writing committee of the D:A:D study group: Cardio- and cerebrovascular events in HIV-1-infected persons. AIDS 2004;18:1811–1817.
6.
Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA: Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003;348:702–710.
7.
Adams HP, Bendixen BH, Kapelle LJ, Biller J, Love BB, Gordon DL, Marsh EE; the TOAST investigators: Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. Stroke 1993;24:35–41.
8.
Bogousslavsky J, van Melle G, Regli F: The Lausanne Stroke Registry: analysis of 1,000 consecutive patients with first stroke. Stroke 1988;19:1083–1092.
9.
Sudlow CLM, Warlow CP: Comparable studies in the incidence of stroke and its pathological types. Results from an international collaboration. Stroke 1997;28:491–499.
10.
Alzamora MT, Sorribes M, Heras H, Vila N, Vicheto M, Forés R, Sánchez-Ojanguren J, Sancho A, Pera G; ‘ISISCOG study group’: Ischemic stroke incidence in Santa Coloma de Gramanet (ISISCOG), Spain. A community based study. BMC Neurol 2008;8:5.
11.
Bazzano LA, Gu D, Reynolds K, Wu X, Chen CS, Duan X, Chen J, Wildman RP, Klag MJ, He J: Alcohol consumption and risk for stroke among Chinese men. Ann Neurol 2007;62:551–552.
12.
Iso H, Baba S, Mannami T, Sasaki S, Okada K, Konishi M, Tsugane S; JPHC Study Group: Alcohol consumption and risk of stroke among middle-aged men: the JPHC study group. Stroke 2004;35:1124–1129.
13.
Mukamal KJ, Ascherio A, Mittleman MA, Conigrave KM, Camargo CA, Kawachi J, Stampfer MJ, Willet WC, Rimm EB: Alcohol and risk for stroke in men: the role of drinking pattern and usual beverage. Ann Intern Med 2005;142:11–19.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.